Clinical Trial

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Study acronym: Awesome
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-09.
Status change: Completed → Recruiting 2024-06-04
Trial Details
NCT Number NCT05284539
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non Small Cell Lung Cancer
Enrollment 760 participants
Start Date 2022-04-01
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-10-10 (estimated)
Updated on ClinicalTrials.gov 2024-06-07